The PROMISE Consortium is an innovative research group led by Co-PIs, Drs. Inga Peter and Jean-Frédéric Colombel of the Icahn School of Medicine at Mount Sinai, Dr. Kenneth Croitoru of Mount Sinai Hospital at the University of Toronto, and Dr. Hamed Khalili of Harvard Medical School. Each site brings a unique cohort to the table, with the goal of identifying unique early biomarkers of Crohn’s Disease with the potential for prediction and prevention.
The three core cohorts are PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects), NHS (The Nurses’ Health Study) and The GEM Project (The Genetic, Environmental, and Microbiome Project). Each prospective or retrospective cohort offers extensive and diverse clinical and omics data to be compared for early biomarkers of CD initiation over different timeframes prior to CD development. These similarities and differences pose a unique opportunity to engage these cohorts synergistically, and all have a proven track record of significant wealth of data and analysis potential over their existence.
Throughout the study, data generation will be coordinated by the consortium, allowing for the integration in complex and informative network anises aimed at strengthening the identification and study of key drivers of CD initiation.
All cohorts involved in the study are approved by their respective IRB or ethics board to perform all involved omics and data analyses.
This work is supported by The Leona M. and Harry B. Charitable Trust.
PROMISE CONSORTIUM 